Fig. 7

IGFBP2 promotes leukemogenesis and resistance to Ara-C. A Confirmation of IGFBP2 knockdown by shRNAs in SKNO-1 and Kasumi-1 cells using western blotting. B Effects of IGFBP2 knockdown on the proliferation of SKNO-1 and Kasumi-1 cells by CCK8 assays. C Effect of silencing IGFBP2 on cell apoptosis in SKNO-1 and Kasumi-1 cells 72 h after siRNA transfection. D The effect of IGFBP2 knockdown on differentiation of SKNO-1 and Kausmi-1 cells. The percentage of CD11b⁺ cells was quantified (right panel). E Wright-Giemsa staining of SKNO-1 and Kausmi-1 cells with or without IGFBP2 knockdown. F CCK-8 assays for SKNO-1 and Kasumi-1 cells transfected with IGFBP2 shRNA or scramble vectors treated with varying concentrations of Ara-C for 48 h. G Western blot analysis for knockdown of Igfbp2 in AML1-ETO9a-driven AML cells. H Kaplan–Meier survival curves of AML1-ETO9a-driven AML mice (n = 10 for each group) after Igfbp2 knockdown. I Wright-Giemsa staining of bone marrow and H&E staining of livers and spleens for Igfbp2-knockdown AML1-ETO9a-driven AML mice. J–O Flow cytometric analysis of the percentage of GFP⁺ AML1-ETO9a AML cells (J–L) and distribution of anti-CD11b-stained GFP + AML cells (M–O) in PB, BM, and SP of AML1-ETO9a-driven AML mice with and without Igfbp2 knockdown 7 weeks after transplantation